Franca Fruzzetti

Dr. Franca Fruzzetti


Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 November 2016 in Gynecological Endocrinology
Verified
Journal Article
Closed access
FFFranca Fruzzetti
Franca Fruzzetti
DPDaria Perini
Daria Perini
MRMarinella Russo
Marinella Russo
FBFiorella Bucci
Fiorella Bucci
AGAngiolo Gadducci
Angiolo Gadducci
Insulin resistance (IR) plays a pivotal role in PCOS. Insulin-sensitizer agents such as metformin and inositols have been shown to improve the endocrine and metabolic aspects of PCOS. The purpose of this study is to compare their effects on the clinical and metabolic features of the women with PCOS. Fifty PCOS women with IR and/or hyperinsulinemia were randomized to treatment with metformin (1500 mg/day) or myo-inositol (4 g/day). IR was defined as HOMA-IR >2.5, while hyperinsulinemia was defined as a value of AUC for insulin after a glucose load over the cutoff of our laboratory obtained in normal women. The Matsusa Index has been calculated. The women have been evaluated for insulin secretion, BMI, menstrual cycle length, acne and hirsutism, at baseline and after 6 months of therapy. The results obtained in both groups were similar. The insulin sensitivity improved in both treatment groups. The BMI significantly decreased and the menstrual cycle was normalized in about 50% of the women. No significant changes in acne and hirsutism were observed. The two insulin-sensitizers, metformin and myo-inositol, show to be useful in PCOS women in lowering BMI and ameliorating insulin sensitivity, and improving menstrual cycle without significant differences between the two treatments.

1 August 2009 in Fertility and Sterility
Verified
Journal Article
Closed access
FFFranca Fruzzetti
Franca Fruzzetti
DPDaria Perini
Daria Perini
VLVeronica Lazzarini
Veronica Lazzarini
DPDonatella Parrini
Donatella Parrini
AGAndrea R. Genazzani
Andrea R. Genazzani

29 November 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
FFFranca Fruzzetti
Franca Fruzzetti
TFTiziana Fidecicchi
Tiziana Fidecicchi
MMMaria Magdalena Montt-Guevara
Maria Magdalena Montt-Guevara
TSTommaso Simoncini
Tommaso Simoncini
Estetrol (E4) is a natural estrogenic steroid that is normally produced by human fetal liver. Recent research has demonstrated that it is a potent, orally bioavailable, natural selective estrogen receptor modulator; it has a moderate affinity for both human estrogen receptor alpha (ERα) and ERβ, with a preference for ERα. Clinical studies have demonstrated possible use as an estrogen in combined oral contraceptives (COC). COCs containing E4 and drospirenone (DRSP) showed a high acceptability, tolerability, and user satisfaction also when compared to COCs containing ethinylestradiol (EE). E4/DRSP effectively inhibits ovulation, with a similar effect on endometrium thickness than that of EE-containing COCs. Low doses (15 mg) of E4 with DRSP (3 mg) showed promising results in term of bleeding pattern and cycle control, also when compared to other COCs containing synthetic estrogens. Moreover, the association has limited effects on serum lipids, liver, SHBG levels, and carbohydrate metabolism. This combination also could drive a lower risk of venous thromboembolism than EE-containing COCs. In this review, we will summarize the actual knowledge about the new E4-containing contraceptive. Further large-scale studies in the full target population are needed to provide more insights into the cardiovascular safety profile and user satisfaction of E4/DRSP.

27 September 2020 in Clinical Drug Investigation
Verified
Journal Article
Closed access
PDF file
FFFranca Fruzzetti
Franca Fruzzetti
TFTiziana Fidecicchi
Tiziana Fidecicchi

1 January 2010 in Contraception
Verified
Journal Article
Closed access
FFFranca Fruzzetti
Franca Fruzzetti
JBJohannes Bitzer
Johannes Bitzer

1 May 2002 in Fertility and Sterility
Verified
Journal Article
Closed access
PDF file
FFFranca Fruzzetti
Franca Fruzzetti
CBChiara Bersi
Chiara Bersi
DPDonatella Parrini
Donatella Parrini
CRCabiria Ricci
Cabiria Ricci
AGAndrea Riccardo Genazzani
Andrea Riccardo Genazzani